Euroz Hartleys Report | 25 October 2021

/in , , /by

Botanix (ASX:BOT) is pleased to share a research report from leading stockbroking firm, Euroz Hartleys, following the release of the Company’s September quarterly update.

Click here to view the report.

Euroz Hartleys Report | 29 September 2021

/in , , /by

Botanix (ASX:BOT) is pleased to share a Quick Comment research report from leading stockbroking firm, Euroz Hartleys, following the Company’s release of a clinical development update on the atopic dermatitis and rosacea programs.

Click here to view the report.

4th International Cannabinoid Derived Pharmaceuticals Summit

/in , , /by

Botanix is delighted to be attending the 4th International Cannabinoid Derived Pharmaceuticals Summit, being held in Boston this week (21-23 September). 

This is the world’s largest conference devoted exclusively to the production of CBD-derived pharmaceuticals for medical conditions. 

Attending industry-leading conferences provides an invaluable opportunity to network with industry peers and key opinion leaders, and to share updates on our leading CBD-based R&D programs in the space of antimicrobial resistance (AMR) and dermatology. 

Find out more about the conference HERE

/in , , /by

Botanix (ASX:BOT) is pleased to share leading stockbroking firm, Euroz Hartleys has initiated coverage of Botanix, with the release of a comprehensive 56-page initial report.

Click here to view the report.

Atopic Dermatitis Update + Presentation

/in , , /by

Botanix Pharmaceuticals has today updated the market with plans for its Atopic Dermatitis (AD) clinical program. This follows important recent learnings on drug dose and formulation design of synthetic CBD in dermatitis applications, together with positive data from a new pilot study conducted in canines with AD.

Canine atopic dermatitis is clinically and immunologically similar to human AD, providing an efficient approach to inform progression of further human studies too.

A recent pilot study of Botanix’s BTX 1204A product in canines (a new higher dose formulation of synthetic CBD for atopic dermatitis, leveraging PermetrexTM), demonstrated significant reductions on average in both the Enhanced Pruritus Score (ESP) and Canine Atopic Dermatitis Extent and Severity Index (CADESI-04) scores over the 28-day treatment period.

Botanix is now advancing plans for a larger BTX 1204A proof of concept canine study in Australia, with goals to confirm and expand safety and efficacy data. Following this, the Company will pursue opportunities for partnering the product in animal health markets and progress towards a Phase 2b study for AD in humans in 1H 2022.

Read today’s ASX release and presentation here.

Investor Conference Call

/in , , /by

Botanix Pharmaceuticals President and Executive Chairman, Vince Ippolito, and Executive Director, Matt Callahan, hosted an investor conference call on Friday 7 May 2021.

You may listen to the audio file here:

Ticker News Interview

/in , , , /by

Botanix Pharmaceutical’s (ASX:BOT) Executive Director, Matt Callahan, spoke with the Ticker News team yesterday to detail the next phase of our BTX 1801 antimicrobial program, which will target nasal decolonisation of Staph aureus in haemodialysis patients.

Investor Presentation + Conference Call

/in , , , /by

Botanix Pharmaceuticals has today released an updated investor presentation and registration details for a conference call with our investors and supporters.

participants can pre-submit questions to be answered at the end of the call, when registering through the link below.

See the updated investor presentation here.

Conference call details:

Date: Friday, 7 May 2021

Time: 11:00am AEST

Registration details:

Participants are encouraged to pre-register for the conference call. Upon registration, participants will receive a unique pin granting fast-track access to the conference call and the opportunity to submit questions to our team.

Register now.

BTX 1801 Clinical Development Update

/in , , , /by

Botanix Pharmaceuticals has today released a comprehensive update and presentation on imminent plans for the BTX 1801 antimicrobial platform program.

The next phase of development for BTX 1801 will focus on targeting the nasal decolonisation of Staph aureus in haemodialysis patients, which represents a significant market opportunity to prevent bloodstream infections in these patients.

Dialysis largely replicates the functions of the kidneys in patients with chronic kidney failure, with dialysis taking over the key functions of the kidneys (including filtering and removing waste materials from the body).  Haemodialysis patients undergoing ongoing dialysis regularly (e.g. three to five times per week), are at a high risk of bloodstream infections, due to their treatment requiring frequent use of catheters which in the first year are routinely central lines with direct access to the heart.

Our team is energised by the opportunity to develop a novel approach for removing sources of bacteria to prevent bloodstream infections in haemodialysis patients – which is desperately needed. Our prior work to examine the unique bactericidal mechanism of action of synthetic cannabidiol provides great confidence for this program too.

Read today’s ASX release and presentation here.

New AMR publication

/in , , , /by

Botanix Pharmaceutical’s ground-breaking research on the antimicrobial potential of cannabidiol (CBD) has been published by a leading South American academic group in BioRxiv.

The BioRxiv article confirms our discovery that synthetic CBD can also kill a select group of Gram-negative bacteria, including the bacteria responsible for the sexually transmitted disease gonorrhoea and the increasingly challenging Clostridioides difficile (C.Diff) infections.

The BioRxiv Paper follows the publication of our research in Nature Research’s peer-reviewed journal Communications Biology in January 2021, which is continuing to drive conversation around the potential of CBD to address antimicrobial resistance, globally.

Read today’s ASX release.